Johnson & Johnson Innovative Medicines (J&J) is preparing to shut down its operations in Nigeria, a move that underscores the mounting struggles multinational companies face in the country.
Insiders told the Commerce and Industry Correspondents Association of Nigeria (CICAN) that the company’s decision is linked to Nigeria’s increasingly challenging economic climate, marked by high inflation, foreign exchange scarcity, escalating production costs, and inconsistent government policies. Collectively, these factors have made running a sustainable business in Nigeria nearly impossible for the healthcare leader.
According to a source, J&J has already cut its local workforce by nearly 80% over the last year. The company’s Consumer Healthcare arm had also exited Nigeria in 2022, signaling ongoing difficulties well before the current development.
“This is bigger than one company’s exit,” the source remarked. “If a global player like Johnson & Johnson finds it unviable to operate here, it raises red flags for other international investors considering Nigeria.”
J&J’s withdrawal is expected to leave a noticeable gap in Nigeria’s healthcare ecosystem, particularly in critical areas such as oncology, immunology, and mental health. The exit could further restrict access to vital medicines and advanced treatment options for Nigerians.